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Background: The original Gore Excluder endoprosthesis (OGE) used both during and briefly after clinical trials was
associated with less sac regression and more sac growth than some other devices, even without apparent endoleaks,
presumably because of transmural movement of serous fluid across the expanded polytetrafluoroethylenematerial. In July
2004, the device was modified to decrease graft permeability. This study evaluated the efficacy of the new Excluder
Low-Permeability Device (ELPD) at 1 year and compared it with the OGE and the Cook Zenith device (ZEN).
Methods: From Food and Drug Administration approval of the Excluder in November 2002 until June 2005, 283 patients
underwent endovascular repair of abdominal aortic aneurysms with the Gore Excluder or the ZEN. Postoperative
surveillance included computed tomographic scans at 1 and 12 months; 181 (64%) patients completed both scans. The
1-month computed tomographic scan served as a baseline, and the minor axis diameter, measured at the largest axial cut
of the abdominal aortic aneurysm, was compared with the samemeasurement at 1 year. A sac size change of 5 mm ormore
was considered significant. Sixty patients treated with the OGE were compared with 72 patients treated with the ELPD.
Forty-nine patients treated during the same time period with the ZEN, known for early sac shrinkage, were used as a
reference. All measurements were performed by one observer from a digital workstation. Wilcoxon signed rank tests
(pairwise) or Kruskal-Wallis tests (three groups) were used for intergroup comparison of continuous variables, whereas
2 statistics or Fisher exact tests were used to compare categorical variables.
Results: Patient age and sex and mean maximum aneurysm diameter at baseline were similar among groups (P .59, .27,
and .46, respectively). Graft migration, stent fractures, acute surgical conversion, late abdominal aortic aneurysm
rupture, or aneurysm-related deaths were not observed. Type II endoleak rates were similar between ELPD and ZEN
(23.6% and 20.4%; P  .68). Although a higher rate of endoleaks was seen with OGE (36.7%), this was not significant
when compared with the other two devices (P .11). At 1 year, patients treated with ELPD had a sac regression rate that
was significantly higher than that for patients treated with OGE (63.9% vs 25%; P < 0.001) and was similar to that for
patients treated with ZEN (65.3%). Significant sac expansion was not observed with ELPD.
Conclusions: At 1 year, similar to ZEN, significant aneurysm sac regression and minimal sac expansion were noted after
endovascular repair of abdominal aortic aneurysms with ELPD. Low-porosity fabric used in the construction of
endoprostheses seems to be an important factor in early aneurysm sac shrinkage. Long-term efficacy regarding the
prevention of sac enlargement remains unclear, and further follow-up is suggested. (J Vasc Surg 2006;44:694-700.)No fewer than 10 commercial devices for endovascular
repair of abdominal aortic aneurysms (EVAR) have been
developed and deployed in US clinical trials.1 Five have
received Food and Drug Administration (FDA) approval,
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694and four remain commercially available. Previous reports
have suggested that endograft type is strongly correlated
with the likelihood of sac regression.2-5 The Excluder en-
dograft (W. L. Gore & Associates, Inc, Flagstaff, Ariz) used
in clinical trials was associated with less sac regression and
more sac growth than some other commercial devices.
Significant sac regression (5 mm) was noted in 23% and
21% of patients, respectively, at 1 and 5 years, and signifi-
cant sac expansion occurred in 3% and 36% at the same time
points after treatment in the Excluder 98-03 Pivotal Trial.6
Of greatest concern, sac growth was occurring even with-
out apparent endoleaks.4-6
Although shrinkage of the aneurysm sac after EVAR
may be desirable, a stable aneurysm has not been linked to
any untoward effects. Sac enlargement, however, implies
increased pressure within the aneurysm sac, and this has
been associated with endoleaks and with sac rupture.7When no endoleak can be identified after aggressive
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endotension.8,9 In permeable stent grafts, endotension is
thought to be the result of transmural movement of serous
fluid across the expanded polytetrafluoroethylene material,
thus resulting in hygroma formation (Fig 1). Aneurysm sac
hygroma has been documented at the time of open re-
pair,10 and in vitro studies demonstrate that the particular
device construct correlates with the degree of plasma per-
meability.11 Apparent endotension has resulted in rupture
of aneurysms treated with other devices in their clinical
trials,12 and sac rupture in the absence of an associated
endoleak has now been observed in three patients treated
with the original Gore Excluder endoprosthesis (OGE).
Clearly, sac growth as a result of this permeability phenom-
enon has been a source of consternation and frustration for
patients, practitioners, and manufacturers alike.
In July 2004, Gore released an updated version of the
Excluder device. The new device incorporates an additional
low-permeability layer to reduce fluid flow across the graft
material. This modification should, in theory, prevent hy-
groma formation and, we hypothesized, would also result
in favorable sac behavior. Implantation of the modified
device began at Northwestern Memorial Hospital and at
theUniversity of PittsburghMedical Center shortly after its
release in July 2004. This study had three objectives: first,
Fig 1. Hygroma formation on an original-design Excluder stent
graft.to evaluate the rates of abdominal aortic aneurysm (AAA)sac change at 12 months after EVAR using the modified
device; second, to compare sac changes before and after
device modification; and third, to compare sac changes
after EVAR with the Excluder device to sac changes with a
device known for early sac shrinkage (Zenith; Cook Medi-
cal, Bloomington, Ind). The main goal was to determine
whether the new alterations incorporated into the con-
struct of the Excluder Low-Permeability Device (ELPD)
would significantly influence the frequency or degree of sac
regression at an early stage after EVAR.
METHODS
From November 2002, after FDA approval, through
the release of the ELPD, until June 2005, 209 consecutive
patients underwent elective endoluminal AAA repair at
these institutions with the Gore Excluder (106 OGE and
103 ELPD). Over a similar time period, 74 patients were
treated with the Cook Zenith device (ZEN). Patients who
were predominantly treated for iliac artery aneurysms or
aortic pseudoaneurysms were excluded from this study.
The institutional review boards at Northwestern University
School of Medicine and the University of Pittsburgh ap-
proved the study protocol. Patient demographics were
compared among the three groups (Table I). Institutional
protocols included, among other measures, patient follow-up
computed tomographic (CT) scans at 1 month and 1 year
after EVAR.Only patients who completed both scanswithin a
4-month window of their scheduled test were included in this
analysis.
Aneurysm anatomy and the presence, or absence, of an
endoleak were determined by CT scans, performed first
without contrast and followed by early- and late-phase
contrast-enhanced imaging. The method used for measur-
ing changes in the dimension of the aneurysm sac was in
accordance with the Society for Vascular Surgery reporting
standards for endovascular aortic aneurysm repair.12 Sac
measurements were completed at a digital workstation
Table I. Patient demographics (mean age, sex, and
aneurysm size) compared for the three endografts:
Zenith, OGE, and ELPD
Variable
OGE
(n  60)
ELPD
(n  72)
Zenith
(n  49)
P
value
Age (y) .59
Mean  SD 74.2  8.1 73.2  8.3 73.0  5.9
Median 74.0 75.0 74.0
Range 59-88 55-88 63-89
Sex (%) .27
Female 26.7 16.7 16.3
Male 73.3 83.3 83.7
Aneurysm size
(mm) .46
Mean  SD 55.2  11.6 52.5  7.7 52.1  7.7
Median 52.0 51.5 51.0
Range 41-106 40-71 43-93
OGE, Original Gore Excluder endoprosthesis; ELPD, Excluder Low-
Permeability Device.by a single observer from each institution. Aneurysm sac
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axis on the largest axial cut of the aneurysm on the
two-dimensional CT scan measured from adventitia to
adventitia. The minor axis measurements were chosen
for primary comparison to avoid overestimation of AAA
size as a result of tortuosity of the aorta.13 We, therefore,
compared the minor axis at the largest area of the AAA
on a baseline postoperative CT scan at 1 month (range,
3-8 weeks) with a second CT scan performed 12 months
later (range, 10-14 months). A sac diameter size change
of 5 mm or more at 12 months compared with the
baseline CT scan was considered significant. Finally, sac
changes after implantation of the ELPD were compared
with sac changes after treatment with the OGE and with
changes after treatment with the ZEN. Clinical, demo-
graphic, and anatomic variables were analyzed for each
device type. Wilcoxon signed rank tests (pairwise) or
Kruskal-Wallis tests (three groups) were used for inter-
group comparison of continuous variables, whereas 2
statistics or Fisher exact tests were used to compare
categorical variables. Continuous variables are summa-
rized as mean  SD, whereas categorical variables are
summarized as counts or percentages.
RESULTS
There were no perioperative aneurysm-related deaths.
No patient experienced AAA rupture or late aneurysm-
related death during follow-up. Twenty-four patients (8%)
died from non–aneurysm-related causes before reaching
1 year, including myocardial infarction (three OGE, six
ELPD, and one ZEN), cancer (threeOGE, two ELPD, and
no ZEN), and other miscellaneous non–aneurysm-related
causes (two OGE, four ELPD, and three ZEN). Three
patients with a baseline aneurysm minor axis diameter less
than 40 mmwho were treated for symptoms (tenderness or
embolization) were excluded from analysis. Seventy-five
(26%) additional patients (26 OGE, 28 ELPD, and 21 ZEN)
were lost to follow-up, did not have a 1- or 12-month CT
scan within the window, or had CT follow-up elsewhere and
films were unavailable for review. When adequate follow-up
data could not be obtained, the patients were excluded
from further analysis. These excluded patients were equally
distributed among the three study groups.
There were 181 patients (60 OGE, 72 ELPD, and 49
ZEN) who completed both the 1- and 12-month CT scans,
and these are the basis for all further review. Patient age was
similar among the groups (OGE, 74.2 8.1 years; ELPD,
73.2 8.3 years; and ZEN, 73.0 5.9 years; P .59). In
terms of sex, there was also no significant disparity noted
among the three groups (Table I). The mean minimum
baseline aneurysm diameter was also similar among groups
(OGE, 55.2  11.6 mm; ELPD, 52.5  7.7 mm; and
ZEN, 52.1  7.7 mm; P  .46). The mean interval
between the 1- and 12-month scans was 11.3 months (SD,
1.5 months) for OGE, 10.7 months (SD, 2.2 months) for
ELPD, and 11.3 months (SD, 2.1 months) for ZEN. No
statistical difference was seen between OGE and ELPD
(P .3), OGE and ZEN (P .98), and ZEN and ELPD(P  .3) when the time interval between the two CT
scans was compared.
Three (2%) type Ia endoleaks were noted at 1 month.
One occurred in a ZEN patient who, despite multiple
coilings and placement of a proximal Palmaz stent, required
eventual graft explantation for continued sac expansion at
12 months. Sac size increased from 93 mm at baseline to
99 mm at 1-year follow-up. A second type Ia leak also
occurred in a ZEN patient. Despite sac regression from
58 to 54 mm, this patient underwent placement of a
proximal Palmaz stent, with a subsequent decrease in the
size of the endoleak. The third type Ia leak occurred in an
ELPD patient. This patient had an increase in sac size
from 45 to 47 mm at 1-year follow-up and is currently
being managed conservatively. All three patients had se-
verely angulated and short infrarenal necks. One (0.5%)
type III endoleak was seen in a ZEN patient. The leak
emanated from a modular disconnect between the main
body and the left iliac limb. This was picked up on the
1-month scan and bridged by using an extension cuff. At
1-year follow-up, there was no endoleak, and the aneurysm
diameter had decreased from 52 to 36 mm.
Forty-three patients (24%; 21 OGE, 15 ELPD, and 7
ZEN) had a type II endoleak on their 1-month CT scan.
Type II endoleaks resolved spontaneously by 12 months in
four OGE, two ELPD, and four ZEN patients. One OGE
patient had a type II endoleak treated with coil emboliza-
tion at 2 months for a 6-mm sac expansion and then
experienced 10 mm of sac shrinkage by 12 months. One
patient treated with ELPD also underwent coil emboliza-
tion of a type II endoleak at 3 months for a 4-mm sac
expansion and experienced 5 mm of sac reduction by 12
months. Sixteen OGE patients, 10 ELPD patients, and 3
ZEN patients had stable type II leaks that remained un-
changed and untreated between the 1- and 12-month
scans. One OGE patient and one ELPD patient developed
new type II leaks at 12 months that were not present on the
Fig 2. Percentage of patients undergoing sac size change at 1
year. OGE, Original Gore Excluder endoprosthesis; ELPD, Ex-
cluder Low-Permeability Device; ZEN, Cook Zenith device.1-month scan.
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sion or regression and the percentage of patients with no
significant sac changes are shown in Fig 2. One patient with
ZEN (2%), 1 patient with OGE (2%), and no patient with
ELPD (0%) experienced significant (5mm) sac expansion
at 1 year. Significant sac size reduction (5 mm) with
OGE, ELPD, and ZEN was noted in 25.0%, 63.9%, and
65.3%, respectively (P  .001). The mean minor axis AAA
size at 1 and 12 months and the percentage decrease in size
from baseline for all three devices are shown in Table II.
The mean minor axis AAA sac size was 55.2 11.6 mm at
baseline and 52.2  11.2 mm at 1 year in patients treated
with OGE, 52.5 7.7 mm at baseline and 44.8 9.6 mm
at 1 year in patients treated with ELPD, and 52.1 7.7mm
at baseline and 43.6 11.0 mm at 1 year in patients treated
with ZEN. The average diameter reduction, when com-
Fig 3. Mean change in aneurysm size at 1 year. OGE, Original
Gore Excluder endoprosthesis; ELPD, Excluder Low-Permeability
Device; ZEN, Cook Zenith device.
Table II. Sac behavior before and after device placement
Variable OGE (n  60) E
Starting aneurysm size (mm)
Mean  SD 55.2  11.6
Median 52.0
Range 41-106
Follow-up aneurysm size (mm)
Mean  SD 52.2  11.2
Median 50.5
Range 32.0-87.0
Change in size (mm)
Mean  SD 3.0  6.3
Median 1.0
Range 22.0-5.0
% change in size
Mean  SD 5.1  10.8 
Median 1.9
Range 36.7-9.6
% patients with a decrease in sac size at 1 y 25.0
Endoleak 1 month (%) 36.7
OGE, Original Gore Excluder endoprosthesis; ELPD, Excluder Low-Perme
*Overall P value.
†Zenith vs ELPD.
‡OGE vs ELPD.pared with baseline, was 3.0  6.3 mm (5.1%) with theOGE, 7.6  6.2 mm (14.8%) with the ELPD, and 8.5 
6.3 mm (16.8%) with ZEN (Fig 3).
The endoleak rate at any one point (all comers) was
36.7% for OGE, 23.6% for ELPD, and 20.4% for ZEN.
Although there was a trend toward a higher leak rate with
the OGE, there was no statistically significant difference
among the devices (Table II).
DISCUSSION
Several recent reports have shown that the change in
aneurysm size after EVAR is device specific.4,5,11 Aneurysm
shrinkage has been reported to be more pronounced with
thicker endografts than those constructed with more perme-
ablematerials. In trials, the Excluder and AneuRx (Medtronic
Vascular, Santa Rosa, Calif ) devices had a sharply lower
incidence of shrinkage when compared with other devices
such as the Talent (Medtronic Vascular) and the ZEN
endografts. The clinical significance of these changes, how-
ever, is not entirely clear. Most would agree that regression
of AAA size implies complete exclusion of the aneurysm sac
and is a useful marker for successful repair. This led the Ad
Hoc Committee for Standardized Reporting Practices in
Vascular Surgery to include size reduction as a criterion for
clinical success.
The OGE was used throughout phase I and phase II
clinical trials. These trials concluded in November 2002,
and FDA approval was granted during the same month. At
5 years, the 98-03 Gore Excluder Pivotal Trial data, as
reported by the clinical test sites, showed no ruptures, one
postprocedure migration, one stent fracture, no graft tears,
and a 10% total endoleak rate (all type II or indeterminate).
The postprocedure conversion rate was 4.3%, and patency
was 100%. The most recent analysis of the 60-month
(n  72) Zenith (n  49) P value* P value† P value‡
.46 .72 .36
 7.7 52.1  7.7
1.5 51.0
0-71 43-93
.001 .27 .001
 9.6 43.6  11.0
5.0 43.0
3-65.0 28.0-99.0
.001 .37 .001
 6.2 8.5  6.3
7.0 9.0
0-2.0 22.0-6.0
.001 .39 .001
 11.9 16.8  12.3
3.1 18.0
3-4.4 44.0-6.0
3.9 65.3 .001 .87 .001
3.6 20.4 .11 .68 .10
Device.LPD
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5
4
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4
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
25.
14.8
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48.
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abilityPivotal Trial data confirms, however, that sac enlargement
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largement (5 mm) at 1, 3, and 5 years after implantation
was 3%, 21%, and 36%, respectively. Of 34 patients with
significant (5-mm) sac growth at 5 years, 18 (53%) of
them had no identifiable endoleak, and device permeability
and endotension were thought to be the culprits. Signifi-
cant sac regression was noted in only 23%, 24%, and 21% of
subjects at those same time points in the Pivotal Trial
(Table III).
The original Excluder device was associated, through-
out all the clinical trials, with some early significant sac
expansion.6 The problem with sac expansion became more
evident at 3 to 4 years.6,7 In Cho and colleagues’ study,7 19
clinical trial patients were followed up for 4 years after
implantation using the original Excluder device. A sac
growth rate of 40% was noted, and endotension was the
apparent culprit in 9 (75%) of 12 of the cases; the other 3
(25%) had type II endoleaks. This sac growth, however, is
not universal, because Melissano et al14 followed up 19
patients for 4 years, and, although sac growth occurred in
association with type IA and type II endoleaks, there was no
case of sac enlargement secondary to endotension. Further-
more, they noted no adverse events when aneurysm sac size
remained unchanged. Relatively poor rates of sac regression
were also noted early on in clinical trials, and corroborating
studies noted sac regression rates of only 14% to 35% at 1
year and 19% to 44% at 2 years after treatment with the
original Excluder device.4,5,7,15
Although no rupture has been reported in the absence
of an endoleak in the 98-03 Pivotal Trial cohort, one
rupture due to endotension has now been reported to the
device manufacturer in the 99-04 phase of the Gore clinical
trial. A second rupture, also without an endoleak, was
reported after FDA approval but before the launch of
ELPD, and a third rupture was reported from outside the
United States. Although no rupture was identified in our
postmarketing OGE patients, some significant sac growth
(2%) and only 25% sac shrinkage were observed. This clearly
suggests that continued close follow-up of this subgroup of
EVAR patients is warranted.
In search of the best explanation for this observation,
Fillinger16 and the Excluder Bifurcated Endoprosthesis
Clinical Investigators recently evaluated the subgroup of
patients from the 98-03 Pivotal Trial who experienced sac
expansion. They used trial core laboratory data to identify
Table III. Aneurysm size change with OGE: site-reported
Change in
aneurysm size
1-6 mo
(N  196),
n (%)
1-12 mo
(N  191),
n (%)
(N
Decrease 24 (12) 44 (23)
No change 168 (86) 142 (74) 1
Increase 4 (2) 5 (3)
OGE, Original Gore Excluder endoprosthesis.
One-month baseline, 5 mm, minor diameter.cases in which the aneurysm sac had grown 5 mm or moreand in which at least 4 years of patient follow-up had taken
place. Three-dimensional morphologic analysis was used
rather than simple diameter measurements. They concluded
that, at a minimum, in 21% of cases, sac growth could be
attributed to nothing else but material permeability and that,
in upwards of 74% of cases, device permeability and endoten-
sion were likely important factors contributing to sac growth.
The ZEN AAA endograft was first introduced in 1993
and was modified shortly thereafter. The device design that
was available in 1997 was used through clinical trials. The
ZEN is constructed by using thick, impermeable Dacron
(DuPont, Wilmington, Del). This endoprosthesis has been
associated with aneurysm sac size regression at an early
stage after its use. Greenberg et al17 reported a significant
sac shrinkage (defined as a change in the size of the major
axis 5 mm) rate of 68% at the 1-year follow-up. A couple
of caveats include, however, that (1) anatomic exclusion
criteria were very stringent during clinical trials, and these
guidelines are generally not as strictly adhered to outside of
trials, and (2) sac size change was considered significant if
the major axis of the sac changed 5 mm or more. We used
theminor axis for comparison, because this is believed to be
a more reliable measure. In a similar study evaluating the
transcontinental Zenith trial data, a 58% sac shrinkage rate
was seen. The devices used were mainly the bifurcated
variety, but a small number of patients were treated with the
aortomonoiliac device.18
This OGE was distributed throughout the United
States after FDA approval at the end of 2002. Delivery of
this device continued through the postmarketing phase
until July 2004. Because of concerns regarding aneurysm
expansion after treatment with the original endoprosthesis,
the device was altered to address the phenomenon of fluid
accumulation within the sac. The ELPD was first delivered
in the United States in July 2004 and then was delivered in
Europe 3 months later. The new low-porosity expanded
polytetrafluoroethylene film incorporated into the device
construct makes the new Excluder less permeable to fluids
when compared with the previous construct. The ELPD
incorporates this less permeable interior layer but maintains
the same luminal and abluminal stent graft surfaces. Bench-
top permeability comparisons performed by Gore by using
pressurized bovine serum demonstrated significant differ-
ences between the devices (OGE, 0.233 g · min1 · cm2;
ELPD, 0.000 g · min1 · cm2). On the basis of our prelim-
luder trial data6
mo
65),
)
1-36 mo
(N  130),
n (%)
1-48 mo
(N  113),
n (%)
1-60 mo
(N  94),
n (%)
25) 31 (24) 23 (20) 20 (21)
65) 72 (55) 53 (47) 40 (43)
10) 27 (21) 37 (33) 34 (36)Exc
1-24
 1
n (%
41 (
08 (
16 (inary data, themodification of the Excluder endograft may be
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the newdevice clearly leads tomore sac size reduction at 1 year
than did the original device. Using the ELPD device, we have
observed that the percentage of patients with significant sac
regression increased from 25% to 64% at 1 year when com-
pared with the older OGE device. This represents a 39%
increase in the number of patients who experience sac regres-
sion when treated with the ELPD. These rates compare well
to the ZEN, for which early favorable sac changes have previ-
ously been documented.
It seems fairly clear that, at least at 1 year, device
permeability does have some influence on sac behavior. It is
unclear, however, what role the presence or absence of an
endoleak plays in sac behavior. Type II endoleaks persisting
out to 1 year were more common in patients treated with
OGE vs patients treated with ELPD or ZEN. It could be
argued that the lack of shrinkage seen in OGE was due not
to material permeability but rather to the fact that this
group had a higher percentage of leaks. As in Fillinger’s
report,16 however, this leak rate cannot fully explain the
nearly threefold improvement in sac size reduction seen
with the ELPD. A counter argument, as has been alluded to
by Fillinger, is that the more permeable material may
actually play a role in perpetuating type II endoleak flow.
Furthermore, sac reduction is not universal with any device.
Some patients, regardless of device type, show no signifi-
cant change despite adequate exclusion.
We also compared our postmarketing results with core
laboratory data from the 98-03 Pivotal Trial.6 The original
Excluder, as expected, performed no differently after mar-
keting than it did during trials, even though Instructions
for Use were not strictly adhered to after FDA approval.
Conversely, the percentage of patients treated with the
ELPD who were found to have significant shrinkage was
much greater than the percentage treated with the OGE in
the Pivotal Trial. In our cohort, at 1 year, 64% of the
patients (46/72) experienced a significant aneurysm sac
diameter reduction when compared with the 1-month
postdeployment CT scan. This compares favorably with the
23% shrinkage rate at 12 months reported in the 98-03
Pivotal Trial, because it represents a threefold increase in
the rate of aneurysm regression over the same time period.
The additional low-permeability layer seems to have
affected the incidence of hygroma and reduced endoten-
sion after AAA exclusion. Limitations included our nearly
36% patient dropout rate. Given our referral patterns, a
large proportion of our patients chose not to travel back to
our centers and elected to continue follow-up at their local
hospitals. Nonetheless, the dropout rate was similar among
the three study groups, and this gives validity to our results.
In addition, our review is preliminary given that the ELPD
has been in use for just over 20 months. Of note, Cho et al7
showed that sac enlargement can have a delayed (3-year)
onset after implantation. Furthermore, sac expansion can
develop even after initial shrinkage. Cho et al noted late sac
growth in three patients in whom re-expansion was noted
after initial shrinkage of more than 5 mm. In one patient,
the sac had regressed by 10 mm at the 6-month follow-up,but it then slowly re-expanded back to baseline by the
fourth year.7 Clearly, more follow-up is necessary in our
patient cohort to ensure that late sac enlargement does not
occur after these encouraging initial results.
Intuitively, AAA regression would seem to be a desir-
able end point of EVAR. However, excessive AAA sac
regressionmay have deleterious consequences. These prob-
lems were well documented in the experience with early
modular endografts.12 It may be that, in fact, a stable sac is
most desirable because this reduces new stresses on the
modular junctions and on the seal zones as sac shrinkage
changes anatomic geometry.19 Again, we recommend
longer follow-up to look for graft migration and compo-
nent disjunction in the face of accelerated sac regression. So
far, in our experience, no graft migration or limb discon-
nection has been noted. With the low migration rates
(2%-3%) reported for the Excluder graft, this study was not
sufficiently powered to address this concern, however. A
prospective study that is currently under way and is spon-
sored by the device manufacturer may provide data that can
answer many of the questions that remain. Unfortunately,
the results from this trial will not be available for a number
of years.
CONCLUSIONS
At 1 year, significant aneurysm sac regression and min-
imal sac expansion were noted after EVAR with ELPD.
Since release of the ELPD for EVAR, no patient has expe-
rienced significant sac growth after implantation in our
experience. Furthermore, up to 64% of patients were noted
to have significant (5-mm) aneurysm sac diameter regres-
sion at 1 year. These rates are an improvement over those
seen with the original Excluder, and they compare favor-
ably to other endoprostheses, such as the ZEN, that also
have low-permeability constructs. Low-porosity fabric seems
to be an important factor in early aneurysm sac shrinkage.
Long-term efficacy regarding prevention of sac enlargement
remains unclear, and further follow-up is suggested. Although
our preliminary data are encouraging, further studies and
more patients with longer follow-up are needed to determine
the continued long-term benefits of the ELPD.
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